Oxbryta
Suspended
This medicine is currently suspended from use in the European Union
Voxelotor
MedicineHumanSuspended
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Oxbryta is a medicine used to treat haemolytic anaemia (excess breakdown of red blood cells) in patients aged 12 years and older who have sickle cell disease. Oxbryta can be given on its own or together with another medicine for sickle cell disease called hydroxycarbamide.
Sickle cell disease is a genetic disease where individuals produce an abnormal form of haemoglobin (the protein in red blood cells that carries oxygen). The red blood cells become rigid and sticky, and change from being disc-shaped to being crescent-shaped (like a sickle). Sickle cell disease is rare, and Oxbryta was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 November 2016. Further information on the orphan designation can be found here: ema.europa.eu/medicines/human/orphan-designations/eu-3-16-1769.
Oxbryta contains the active substance voxelotor.
Oxbryta can only be obtained with a prescription and treatment should be started by a doctor experienced in the treatment of sickle cell disease.
The medicine is available as tablets to be taken by mouth and the usual recommended dose is 1,500 mg taken once daily.
For more information about using Oxbryta, see the package leaflet or contact your doctor or pharmacist.
In sickle cell disease, sickling of the red blood cells occurs when the abnormal haemoglobin releases its oxygen and then clumps together to form rigid chains that make the cells change shape and cause them to break down more quickly. As well as potentially blocking blood vessels, this leads to lower numbers of red blood cells and less working haemoglobin able to carry oxygen around the body. The active substance in Oxbryta, voxelotor, works by improving the ability of the haemoglobin to hold on to oxygen, and preventing it from forming chains. This helps the red blood cells to maintain normal shape and flexibility, reducing their excess breakdown and improving their lifespan.
Oxbryta has been shown to improve haemolytic anaemia in a main study involving 247 patients aged 12 to 64 years with sickle cell disease. Patients were given Oxbryta or placebo (a dummy treatment) as well as continuing hydroxycarbamide treatment if they were already receiving it. At the start of treatment, the average haemoglobin level was 8.5 g per dL of blood. After treatment for 24 weeks, the haemoglobin level had improved by at least 1 g per dL in around 51% of the group given Oxbryta 1,500 mg daily (46 of 90 patients) versus 6.5% of those taking placebo (6 of 92). Other measures also showed reductions in red blood cell breakdown with Oxbryta.
The most common side effects with Oxbryta (which may affect more than 1 in 10 people) are headache, diarrhoea and abdominal (belly) pain. The most serious side effects, affecting around 1 in 100 people, include headache and hypersensitivity (allergic) reactions.
For the full list of side effects and restrictions with Oxbryta, see the package leaflet.
Current treatments for sickle cell disease already include medicines to prevent the painful crises caused when sickle cells block blood supply to vital organs. However, there is an unmet medical need for treatments to manage the anaemia associated with the condition, which leads to tiredness and chronic pain as well as contributing to other complications. Oxbryta has been shown to improve anaemia by increasing haemoglobin levels and reducing red cell breakdown. It is not yet clear to what extent this will improve clinical symptoms and quality of life in the longer term, since the medicine’s action may also reduce the ability of haemoglobin to release oxygen to the body’s tissues. Nonetheless, since the side effects seem to be limited and manageable, the European Medicines Agency decided that Oxbryta’s benefits are greater than its risks and it can be authorised for use in the EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oxbryta have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Oxbryta are continuously monitored. Suspected side effects reported with Oxbryta are carefully evaluated and any necessary action taken to protect patients.
Oxbryta received a marketing authorisation valid throughout the EU on 14 February 2022.
Product information
Latest procedure affecting product information:
PSUSA/00010983/202308
17/05/2024
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Oxbryta
- Active substance
- Voxelotor
- International non-proprietary name (INN) or common name
- Voxelotor
- Therapeutic area (MeSH)
- Anemia
- Anemia, Hemolytic
- Anemia, Sickle Cell
- Anatomical therapeutic chemical (ATC) code
- B06AX03
Pharmacotherapeutic group
Other hematological agentsTherapeutic indication
Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
News on Oxbryta
This page was last updated on